Literature DB >> 20376043

Molecular oracles for multiple sclerosis therapy.

Hartmut Wekerle, Reinhard Hohlfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20376043     DOI： 10.1038/nm0410-376

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

Review 1.  Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

Authors:  Richard A Rudick; Chris H Polman
Journal:  Lancet Neurol       Date:  2009-06       Impact factor: 44.182

2.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.

Authors:  M Comabella; J D Lünemann; J Río; A Sánchez; C López; E Julià; M Fernández; L Nonell; M Camiña-Tato; F Deisenhammer; E Caballero; M T Tortola; M Prinz; X Montalban; R Martin
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

3.  Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production.

Authors:  Adriana A Byrnes; Justin C McArthur; Christopher L Karp
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

Review 4.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

5.  IFN-beta inhibits human Th17 cell differentiation.

Authors:  Vinod S Ramgolam; Yonggang Sha; Jianping Jin; Xin Zhang; Silva Markovic-Plese
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

6.  T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Authors:  Luca Durelli; Laura Conti; Marinella Clerico; Daniela Boselli; Giulia Contessa; Paolo Ripellino; Bruno Ferrero; Pierre Eid; Francesco Novelli
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

Review 7.  Development of biomarkers in multiple sclerosis.

Authors:  Bibiana Bielekova; Roland Martin
Journal:  Brain       Date:  2004-06-04       Impact factor: 13.501

8.  TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.

Authors:  Klaus-Peter Wandinger; Jan D Lünemann; Oliver Wengert; Judith Bellmann-Strobl; Orhan Aktas; Alexandra Weber; Eva Grundström; Stefan Ehrlich; Klaus-D Wernecke; Hans-Dieter Volk; Frauke Zipp
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Transcription-based prediction of response to IFNbeta using supervised computational methods.

Authors:  Sergio E Baranzini; Parvin Mousavi; Jordi Rio; Stacy J Caillier; Althea Stillman; Pablo Villoslada; Matthew M Wyatt; Manuel Comabella; Larry D Greller; Roland Somogyi; Xavier Montalban; Jorge R Oksenberg
Journal:  PLoS Biol       Date:  2004-12-28       Impact factor: 8.029

10.  A rush to judgment on Th17.

Authors:  Lawrence Steinman
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307
View more
  1 in total

Review 1.  The conundrum of iron in multiple sclerosis--time for an individualised approach.

Authors:  Susan J van Rensburg; Maritha J Kotze; Ronald van Toorn
Journal:  Metab Brain Dis       Date:  2012-03-17       Impact factor: 3.584
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.